-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M

Benzinga·04/07/2026 12:37:49
Listen to the news

TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.